换一批
换一批A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.
作者：
主题词
成年人(Adult);老年人(Aged);抗体, 单克隆(Antibodies, Monoclonal);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);乳腺肿瘤(Breast Neoplasms);趋化因子CXCL10(Chemokine CXCL10);趋化因子CXCL9(Chemokine CXCL9);细胞毒性, 免疫(Cytotoxicity, Immunologic);酶联免疫吸附测定(Enzyme-Linked Immunosorbent Assay);女(雌)性(Female);人类(Humans);干扰素γ(Interferon-gamma);白细胞介素2(Interleukin-2);杀伤细胞, 天然(Killer Cells, Natural);中年人(Middle Aged);RNA, 信使(RNA, Messenger);逆转录聚合酶链反应(Reverse Transcriptase Polymerase Chain Reaction);挽救疗法(Salvage Therapy)
DOI
10.1007/s10549-008-0251-7
PMID
19051009
发布时间
2021-10-20
- 浏览19
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
